NEW YORK--(EON: Enhanced Online News)--FlowAid Medical Technologies Corp. announced positive results from a study of the usage of its FA100 Sequential Contraction Compression Device among a group of patients with diabetic peripheral neuropathy. Following 30 days of supervised home use, the patients reported significantly less pain, less reliance on analgesics and fewer nights of disturbed sleep.
“The new research could alter the way Diabetic Neuropathy is understood and treated. Use of the FA100 SCCD on patients suffering from hypoesthetic DPN restores sensation. We are planning larger studies that will bear out our findings”
The study, “Sequential Contraction Compression Device Therapy affects Symptomatic Diabetic Peripheral Neuropathy”, published in the Journal of Diabetic Complications & Medicine challenges the traditional understanding that diabetic peripheral neuropathy is a metabolic disease. Building upon past studies that show that micro ischemia, and pathologic alterations of the micro vessels play an important role in the progression of the disease, the authors “hypothesize that by hyperperfusing the limb, excess arterial pressure is shifted into the microvasculature where it is then able to regenerate hypoxic and ischemic nerve tissue. Neuroregeneration would have an effect on objective examinations such as NCV, but it is expected that these results would lag, perhaps even significantly behind the subjective results.”
Diabetic Peripheral Neuropathy is a debilitating complication of diabetes affecting almost 50% of diabetes patients and has been implicated in the formation of Diabetic Foot Ulcers.
FlowAid CEO Jacob Brezel: “The new research could alter the way Diabetic Neuropathy is understood and treated. Use of the FA100 SCCD on patients suffering from hypoesthetic DPN restores sensation. We are planning larger studies that will bear out our findings”.
The FA100 SCCD is a portable handheld 4-channel device that produces a sequence of muscular contractions through electrodes that are placed on the calf muscles. The sequence of the contractions remove deoxygenated blood so that oxygen and nutrient rich blood can be delivered and allowing the natural healing process to begin. It is easy to use, allows complete patient mobility and operates without any external pressure to the leg. Trials and evaluations are ongoing with professional interest on every continent.
FlowAid Medical Technologies Corp. is an emerging growth company focused on treating blood circulatory disorders of the extremities by continuously upgrading current medical solutions with new innovative cutting edge technologies. Our mission is to improve the quality of patient care and the productivity of health care delivery through the development of certain non-invasive medical devices and procedures for increasing blood flow and circulatory enhancement. FlowAid has perfected a new approach for the administration of sequential compression therapy and expects it to become the new standard of care for circulatory disorders of the extremities including Venous and Arterial Diseases, Chronic Ulcers, Lymphadema and for the prevention of DVT (Deep Vein Thrombosis) based upon many years of R&D, the involvement of many multidisciplinary professionals and patient feedback.